These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15206107)

  • 1. Ruthenium anticancer drugs.
    Alessio E; Mestroni G; Bergamo A; Sava G
    Met Ions Biol Syst; 2004; 42():323-51. PubMed ID: 15206107
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
    Bergamo A; Sava G
    Dalton Trans; 2011 Aug; 40(31):7817-23. PubMed ID: 21629963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruthenium complexes can target determinants of tumour malignancy.
    Bergamo A; Sava G
    Dalton Trans; 2007 Apr; (13):1267-72. PubMed ID: 17372640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor titanium compounds and related metallocenes.
    Caruso F; Rossi M
    Met Ions Biol Syst; 2004; 42():353-84. PubMed ID: 15206108
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
    Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
    J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruthenium-based chemotherapeutics: are they ready for prime time?
    Antonarakis ES; Emadi A
    Cancer Chemother Pharmacol; 2010 May; 66(1):1-9. PubMed ID: 20213076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
    Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
    [No Abstract]   [Full Text] [Related]  

  • 8. A theoretical study on the hydrolysis process of the antimetastatic ruthenium(III) complex NAMI-A.
    Chen J; Chen L; Liao S; Zheng K; Ji L
    J Phys Chem B; 2007 Jul; 111(27):7862-9. PubMed ID: 17579393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAMI-A preferentially reacts with the Sp1 protein: understanding the anti-metastasis effect of the drug.
    Yuan S; Chen S; Wu H; Jiang H; Zheng S; Zhang Q; Liu Y
    Chem Commun (Camb); 2020 Jan; 56(9):1397-1400. PubMed ID: 31912815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A.
    Ravera M; Baracco S; Cassino C; Zanello P; Osella D
    Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
    Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquation of the ruthenium-based anticancer drug NAMI-A: a density functional study.
    Besker N; Coletti C; Marrone A; Re N
    J Phys Chem B; 2008 Apr; 112(13):3871-5. PubMed ID: 18331025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteins.
    Casini A; Temperini C; Gabbiani C; Supuran CT; Messori L
    ChemMedChem; 2010 Dec; 5(12):1989-94. PubMed ID: 20931644
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
    Peacock AF; Sadler PJ
    Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.
    Piccioli F; Sabatini S; Messori L; Orioli P; Hartinger ChG; Keppler BK
    J Inorg Biochem; 2004 Jun; 98(6):1135-42. PubMed ID: 15149825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy.
    Babak MV; Ang WH
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
    Bouma M; Nuijen B; Jansen MT; Sava G; Flaibani A; Bult A; Beijnen JH
    Int J Pharm; 2002 Nov; 248(1-2):239-46. PubMed ID: 12429477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu.
    Vergara A; D'Errico G; Montesarchio D; Mangiapia G; Paduano L; Merlino A
    Inorg Chem; 2013 Apr; 52(8):4157-9. PubMed ID: 23517183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.